PL2030622T3 - Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu - Google Patents

Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Info

Publication number
PL2030622T3
PL2030622T3 PL08167618T PL08167618T PL2030622T3 PL 2030622 T3 PL2030622 T3 PL 2030622T3 PL 08167618 T PL08167618 T PL 08167618T PL 08167618 T PL08167618 T PL 08167618T PL 2030622 T3 PL2030622 T3 PL 2030622T3
Authority
PL
Poland
Prior art keywords
progesterone
dosage
indication
treatment
brain injury
Prior art date
Application number
PL08167618T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PL2030622T3 publication Critical patent/PL2030622T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL08167618T 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu PL2030622T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP08167618A EP2030622B1 (en) 2005-03-24 2006-03-24 Indication of dosage of progesterone in the treatment of a traumatic brain injury

Publications (1)

Publication Number Publication Date
PL2030622T3 true PL2030622T3 (pl) 2011-07-29

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Country Status (15)

Country Link
US (4) US20090325920A1 (pl)
EP (5) EP2030622B1 (pl)
JP (5) JP5295755B2 (pl)
AT (2) ATE499104T1 (pl)
AU (2) AU2006226774B2 (pl)
CA (2) CA2602950C (pl)
CY (2) CY1111478T1 (pl)
DE (1) DE602006020353D1 (pl)
DK (2) DK2030622T3 (pl)
ES (2) ES2428313T3 (pl)
HR (2) HRP20120688T1 (pl)
PL (2) PL2030622T3 (pl)
PT (2) PT2030622E (pl)
RS (1) RS52471B (pl)
WO (2) WO2006102596A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2030622T3 (pl) 2005-03-24 2011-07-29 Univ Emory Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
AU2009219230A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
RU2366466C1 (ru) * 2008-03-25 2009-09-10 Олег Васильевич Онысько Способ лечения черепно-мозговой травмы
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
EP3689364A1 (en) 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
AU2012249397B2 (en) * 2011-04-27 2017-03-30 Northwestern University Methods of treating Alzheimer's disease, Huntington's disease, autism, or other disorders
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US20150018327A1 (en) 2012-01-23 2015-01-15 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
JP6169110B2 (ja) 2012-02-29 2017-07-26 ビー．ブラウン メルズンゲン アーゲーＢ．Ｂｒａｕｎ Ｍｅｌｓｕｎｇｅｎ Ａｇ ホルモン含有エマルジョン
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
CA2882708A1 (en) * 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US9512134B2 (en) 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
EP3426257A4 (en) 2016-03-08 2019-11-13 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX378566B (es) 2016-05-19 2025-03-11 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX383650B (es) 2016-08-01 2025-03-14 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EA201990425A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
ES3008466T3 (en) 2018-01-31 2025-03-24 Tenacia Biotechnology Hong Kong Co Ltd Spiro-lactam nmda receptor modulators and uses thereof
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
JP2024542727A (ja) * 2021-12-02 2024-11-15 マーベルバイオーム・インコーポレイテッド 迷走神経関連疾患、障害、及び状態を治療するための方法、及び微生物叢組成物、成分、または代謝産物の使用
US20230293722A1 (en) * 2022-01-05 2023-09-21 Metaqor Llc Compositions and Methods for Treating Neurological-associated Disorders
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
DK0680327T3 (da) * 1993-01-19 2005-01-03 Endorech Inc Terapeutiske anvendelser af og leveringssystemer for dehydroepiandrosteron
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
BR9608592A (pt) * 1995-06-06 1999-06-29 Cocensys Inc Esteróides neuroativos da série do androstano e do pregnano
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
CA2256365A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
DE69809223T2 (de) 1997-05-02 2003-07-24 Wyeth, Madison 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
PL2030622T3 (pl) * 2005-03-24 2011-07-29 Univ Emory Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
JP5295755B2 (ja) 2013-09-18
ES2392454T3 (es) 2012-12-10
JP2011225629A (ja) 2011-11-10
HK1128242A1 (en) 2009-10-23
US20120289491A1 (en) 2012-11-15
US8614203B2 (en) 2013-12-24
EP2030622A1 (en) 2009-03-04
WO2006102644A9 (en) 2006-11-23
HK1112579A1 (en) 2008-09-12
AU2006226774A1 (en) 2006-09-28
JP5496407B2 (ja) 2014-05-21
DK1868614T3 (da) 2012-11-12
AU2006226811A1 (en) 2006-09-28
JP2014055183A (ja) 2014-03-27
DK2030622T3 (da) 2011-05-02
ATE499104T1 (de) 2011-03-15
WO2006102596A3 (en) 2007-01-18
EP2030622B1 (en) 2011-02-23
CY1113253T1 (el) 2016-04-13
JP2013234191A (ja) 2013-11-21
JP2008534512A (ja) 2008-08-28
ATE520404T1 (de) 2011-09-15
US20120245133A1 (en) 2012-09-27
JP2008534515A (ja) 2008-08-28
EP1871382A2 (en) 2008-01-02
HRP20110198T1 (hr) 2011-04-30
EP1871382B1 (en) 2011-08-17
US20090221544A1 (en) 2009-09-03
PT2030622E (pt) 2011-06-02
CA2602950A1 (en) 2006-09-28
WO2006102644A3 (en) 2007-03-01
RS52471B (sr) 2013-02-28
PT1868614E (pt) 2012-11-23
EP2431042B1 (en) 2013-06-26
CY1111478T1 (el) 2015-08-05
AU2006226774B2 (en) 2010-12-02
HRP20120688T1 (hr) 2012-09-30
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
WO2006102596A2 (en) 2006-09-28
HK1112581A1 (en) 2008-09-12
EP2431042A1 (en) 2012-03-21
EP1868614B1 (en) 2012-08-08
WO2006102644A2 (en) 2006-09-28
CA2601715A1 (en) 2006-09-28
EP2494976A1 (en) 2012-09-05
AU2006226811B2 (en) 2010-11-25
DE602006020353D1 (de) 2011-04-07
JP5394059B2 (ja) 2014-01-22
US20090325920A1 (en) 2009-12-31
CA2602950C (en) 2012-10-30
EP1868614A2 (en) 2007-12-26
PL1868614T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
PL2030622T3 (pl) Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
TW200740804A (en) Glucokinase activators
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2007134203A3 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
PL1704860T3 (pl) Pochodne benzamidyny do leczenia i zapobiegania zapaleniu śluzówki
MX2019003751A (es) Proteina terapeutica.
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
Chefranova et al. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury